Brexit: EMA to lose 30% Staff?
Recommendation
28/29 May 2024
Copenhagen, Denmark
Supervision of the Pharmaceutical Quality System: Challenges and Opportunities
The European Medicines Agency published a press release and announced the next phase of its business continuity plan. The launch of this next phase will be on 1 October 2018 at the latest.
The plan is important to focus on core activities related to the evaluation and supervision of medicines. One of the biggest challenges is the loss of staff members caused by the relocation of the Agency to Amsterdam. It is now clear that "the Agency will lose more staff than initially anticipated". It is expected to lose about 30% of staff. What makes it even more challenging is the fact that people already started to leave the Agency. As a consequence, EMA will have to further "reprioritise its resources to fully maintain its core activities".
What are the consequences?
EMA will start to temporarily scale back or suspend additional activities like for example:
- Collaboration at international level
- Harmonisation of global medicine regulation (EMA will only take a "reactive role")
- Development and revision of guidelines
- Holding of non-product-related working parties
- Organisation and attendance at stakeholder meetings
- Clinical data publication
Source: EMA press release "Brexit preparedness: EMA to further temporarily scale back and suspend activities".
Related GMP News
06.05.2024EMA Plans for the next three Years
30.04.2024Lean GMP: is "right-sizing" GMP and Compliance possible?
24.04.2024Unexpected Deviations: the Role of the QP
10.04.2024FDA's current Thinking on KPIs and Quality Metrics
21.02.2024What is the African Medicines Agency?
08.02.2024FDA Revision to the Guidance on Quality Considerations for Ophthalmic Drug Products